Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
7.4
5.2
Journals
Cancers
Special Issues
Management of Gastric Cancer
share announcement

Management of Gastric Cancer

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".

Deadline for manuscript submissions: closed (30 November 2023) | Viewed by 9554

Special Issue Editors

Prof. Dr. Sergio Alfieri

E-Mail Website
Guest Editor
1. Digestive Surgery Unit, Department of Surgery, Gemelli Pancreatic Center, CRMPG (Advanced Pancreatic Research Center), Fondazione Policlinico Universitario "Agostino Gemelli" IRCCS, Largo Agostino Gemelli 8, 00168 Rome, Italy
2. Chirurgia Digestiva, Dipartimento di Medicina e Chirurgia Traslazionale, Università Cattolica del Sacro Cuore, Fondazione Policlinico Universitario “A. Gemelli” IRCCS, 00168 Rome, Italy
Interests: surgical oncology; gastric cancer; new technologies
Dr. Fausto Rosa

E-Mail Website
Guest Editor
1. Dipartimento di Medicina e Chirurgia Traslazionale, Università Cattolica del Sacro Cuore, 00168 Rome, Italy
2. Emergency and Trauma Surgery Unit, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, 00168 Rome, Italy
Interests: surgical oncology; emergency and trauma surgery; acute care surgery; gastric cancer; new technologies
Special Issues, Collections and Topics in MDPI journals
Dr. Valerio Papa

E-Mail Website
Guest Editor
1. Digestive Surgery Unit, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, 00168 Rome, Italy
2. Chirurgia Digestiva, Dipartimento di Medicina e Chirurgia Traslazionale, Università Cattolica del Sacro Cuore, Fondazione Policlinico Universitario “A. Gemelli” IRCCS, 00168 Rome, Italy
Interests: surgical oncology; gastric cancer; new technologies

Special Issue Information

Dear Colleagues,

(1) Gastric cancer remains an oncological burden with a low survival rate.

New epidemiological trends include an upward shift in the location of the primary tumour and a relative increase in advanced and diffuse-type tumours. These trends dictate the modification of surgical techniques towards a more individualized treatment approach.

Multidisciplinary management is essential to offer an adjusted treatment to the patient general condition and the tumor stage. New minimally invasive surgical treatments help to reduce surgical trauma and improve post-operative patient recovery. Oncological treatments have also evolved and definitive treatment by radio-chemotherapy can be proposed in specific cases.

We are pleased to invite you to contribute to this Special Issue, with high-quality original papers, as well as review articles, focusing on optimal patient selection and treatment strategies.

As an eminent scientist in the field, we would like to invite you to contribute to the Special Issue by submitting an article that falls within your area of expertise. Please feel free to nominate someone from your team, as co-author, if needed.

(2) Aim of the Special Issue and how the subject relates to the journal’s scope: Please make sure that your Special Issue is within the scope of the journal. You can check the scope in the journal menu: Aims and Scope. Additionally, the scope should not be too broad or too narrow. The aim is to have a collection of at least 10 articles, which we would assist with and work together with you to achieve, and the Special Issue can be printed in book form if this number is reached.

This Special Issue aims to present the most common advanced current options for the treatment of Gastric Cancer and the main open questions in the management of these patients, trying to depict an update of the available algorithms for everyday practice. Moreover, we summarize the design and preliminary results of the randomized trials in progress that will hopefully give definitive answers to the most debated issues in the field.

(3) Suggested themes and article types for submissions.

In this Special Issue, original research articles and reviews are welcome. Research areas may include (but are not limited to) the following:

  • Molecular Biology;
  • Neoajuvant therapy;
  • Gastric Cancer Surgery;
  • New Technologies;
  • Adjuvant therapy.

We look forward to receiving your contributions.

Prof. Dr. Sergio Alfieri
Dr. Fausto Rosa
Dr. Valerio Papa
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • surgery
  • innovation
  • integrated treatments
  • molecular biology
  • new technologies

Related Special Issue

Published Papers (5 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

13 pages, 1337 KiB  
Article
Neoadjuvant Chemotherapy Followed by Gastrectomy for Cytology-Positive Gastric Cancer without Any Other Non-Curative Factors in a Western Setting: An International Eastern European Cohort Study
by Augustinas Bausys, Toomas Ümarik, Oleksii Dobrzhanskyi, Martynas Luksta, Yourii Kondratskyi, Arvo Reinsoo, Mihhail Vassiljev, Bernardas Bausys, Klaudija Bickaite, Kornelija Rauduvyte, Raminta Luksaite-Lukste, Rimantas Bausys and Kestutis Strupas
Cancers 2023, 15(24), 5794; https://doi.org/10.3390/cancers15245794 - 11 Dec 2023
Viewed by 1007
Abstract
The optimal approach for treating cytology-positive (Cy1) gastric cancer (GC) patients without additional non-curative factors remains uncertain. While neoadjuvant chemotherapy followed by gastrectomy shows promise, its suitability for Western patients is not well supported by existing data. To address this knowledge gap, a [...] Read more.
The optimal approach for treating cytology-positive (Cy1) gastric cancer (GC) patients without additional non-curative factors remains uncertain. While neoadjuvant chemotherapy followed by gastrectomy shows promise, its suitability for Western patients is not well supported by existing data. To address this knowledge gap, a cohort study was conducted across four major GC treatment centers in Lithuania, Estonia, and Ukraine. Forty-three consecutive Cy1 GC patients who underwent neoadjuvant chemotherapy between 2016 and 2020 were enrolled. The study evaluated overall survival (OS), progression-free survival (PFS), cytology status conversion, and major pathological response rates, along with the factors influencing these outcomes. All patients underwent surgery post-neoadjuvant chemotherapy, with 53.5% experiencing cytological status conversion and 23.3% achieving a major pathological response. The median OS and PFS were 20 (95% CI: 16–25) and 19 (95% CI: 11–20) months, respectively. Conversion to negative cytology significantly reduced the relative risk of peritoneal progression (RR: 0.11; 95% CI: 0.03–0.47, p = 0.002). The study suggests that neoadjuvant chemotherapy followed by gastrectomy holds promise as a treatment option for Cy1 GC without additional non-curative factors, associating cytology status conversion with improved long-term outcomes and reduced peritoneal relapse risk. Full article
(This article belongs to the Special Issue Management of Gastric Cancer)
►▼ Show Figures

Figure 1

11 pages, 2865 KiB  
Article
MUC1 Expressions and Its Prognostic Values in US Gastric Cancer Patients
by Young-Il Kim, Robert Luke Pecha, Tara Keihanian, Michael Mercado, S. Valeria Pena-Munoz, Kailash Lang, George Van Buren, Sadhna Dhingra and Mohamed O. Othman
Cancers 2023, 15(4), 998; https://doi.org/10.3390/cancers15040998 - 4 Feb 2023
Cited by 4 | Viewed by 1756
Abstract
This study aims to evaluate the prognostic value of MUC expression in US GC patients. A total of 70 tumor specimens were collected from GC patients who underwent surgery or endoscopic resection between 2013 and 2019 at a tertiary referral center in the [...] Read more.
This study aims to evaluate the prognostic value of MUC expression in US GC patients. A total of 70 tumor specimens were collected from GC patients who underwent surgery or endoscopic resection between 2013 and 2019 at a tertiary referral center in the US. MUC expression status including MUC1, MUC2, MUC5AC, and MUC6 was evaluated by immunohistochemical staining. The positive rates of MUC1, MUC2, MUC5AC, and MUC6 were 71.4%, 78.6%, 74.3%, and 33.3%, respectively. Patients with positive MUC1 expression had a significantly higher rate of aggressive pathologic features including diffuse-type cancer (42.0% vs. 0%; p < 0.001), advanced GC (80.0% vs. 30.0%, p < 0.001), lymph node metastasis (62.0% vs. 20.0%; p = 0.001), and distant metastasis (32.0% vs. 5.0%; p = 0.017) compared with those with negative MUC1 expression. However, the differences in the pathologic features were not observed according to MUC2, MUC5AC, and MUC6 expression status. In early gastric cancer (EGC), patients with a high level of MUC1 expression showed a higher rate of lymphovascular invasion (71.4% vs. 21.4%; p = 0.026) and EGC meeting non-curative resection (85.7% vs. 42.9%; p = 0.061) than those with negative MUC1. In US GC patients, MUC1 expression is associated with aggressive pathological features, and might be a useful prognostic marker. Full article
(This article belongs to the Special Issue Management of Gastric Cancer)
►▼ Show Figures

Figure 1

10 pages, 2143 KiB  
Article
Cachexia Index as a Prognostic Indicator in Patients with Gastric Cancer: A Retrospective Study
by Can Gong, Qianyi Wan, Rui Zhao, Xinrong Zuo, Yi Chen and Tao Li
Cancers 2022, 14(18), 4400; https://doi.org/10.3390/cancers14184400 - 10 Sep 2022
Cited by 11 | Viewed by 1960
Abstract
The current diagnostic criteria for cancer cachexia are inconsistent, and the prognostic value of cachexia in gastric cancer (GC) is controversial. This study aimed to investigate the prognostic value of the cachexia index (CXI) in patients with GC. We calculated the CXI as [...] Read more.
The current diagnostic criteria for cancer cachexia are inconsistent, and the prognostic value of cachexia in gastric cancer (GC) is controversial. This study aimed to investigate the prognostic value of the cachexia index (CXI) in patients with GC. We calculated the CXI as skeletal muscle index (SMI) × serum albumin/neutrophil-lymphocyte ratio (NLR), and a total of 161 and 163 patients were included in the high and low CXI groups, respectively. Low CXI was significantly associated with a more advanced tumor–node–metastasis (TNM) stage, a higher level of serum C-reactive protein, serum interleukin-6, and NLR, but also a decreased level of serum prealbumin and albumin. In addition, patients in the low CXI group were more likely to have postoperative pulmonary infections (9.8% vs. 3.7%, p = 0.03). Cox proportional analyses indicated that patients with low CXI (HR 0.45, 95% CI 0.29 to 0.69; p < 0.001) or TNM stage III+IV (HR 4.38, 95% CI 2.54 to 7.55; p < 0.001) had a significantly poorer overall survival (OS). Kaplan–Meier survival curves suggested that patients with low CXI had a significantly decreased OS, which was not affected by subgroup analyses of different sex, age, cachexia, body mass index (BMI), and TNM stage. Furthermore, low CXI combined with cachexia, low BMI, or TNM stage III+IV caused the worst OS in each subgroup analysis, respectively. Our study demonstrated that CXI had a good prognostic value in GC. Greater attention should be paid to patients with low CXI, particularly those combined with cachexia, low BMI, or TNM stage III+IV. Full article
(This article belongs to the Special Issue Management of Gastric Cancer)
►▼ Show Figures

Figure 1

Review

Jump to: Research

16 pages, 826 KiB  
Review
Current Progress on Predictive Biomarkers for Response to Immune Checkpoint Inhibitors in Gastric Cancer: How to Maximize the Immunotherapeutic Benefit?
by Yongqing Liu, Pengbo Hu, Liang Xu, Xiuyuan Zhang, Zhou Li, Yiming Li and Hong Qiu
Cancers 2023, 15(8), 2273; https://doi.org/10.3390/cancers15082273 - 13 Apr 2023
Cited by 3 | Viewed by 2225
Abstract
Gastric cancer is the fifth most prevalent cancer and the fourth leading cause of cancer death globally. Delayed diagnosis and pronounced histological and molecular variations increase the complexity and challenge of treatment. Pharmacotherapy, which for a long time was systemic chemotherapy based on [...] Read more.
Gastric cancer is the fifth most prevalent cancer and the fourth leading cause of cancer death globally. Delayed diagnosis and pronounced histological and molecular variations increase the complexity and challenge of treatment. Pharmacotherapy, which for a long time was systemic chemotherapy based on 5-fluorouracil, is the mainstay of management for advanced gastric cancer. Trastuzumab and programmed cell death 1 (PD-1) inhibitors have altered the therapeutic landscape, contributing to noticeably prolonged survivorship in patients with metastatic gastric cancer. However, research has revealed that immunotherapy is only beneficial to some individuals. Biomarkers, such as programmed cell death ligand 1 (PD-L1), microsatellite instability (MSI), and tumor mutational load (TMB), have been shown to correlate with immune efficacy in numerous studies and are increasingly employed for the selection of patients most likely to respond to immunotherapy. Gut microorganisms, genetic mutations like POLE/POLD1 and NOTCH4, tumor lymphoid infiltrating cells (TILs), and other novel biomarkers have the potential to develop into new predictors. Prospective immunotherapy for gastric cancer should be guided by a biomarker-driven precision management paradigm, and multidimensional or dynamic marker testing could be the way to go. Full article
(This article belongs to the Special Issue Management of Gastric Cancer)
►▼ Show Figures

Figure 1

24 pages, 399 KiB  
Review
The Role of Surgery in the Management of Gastric Cancer: State of the Art
by Fausto Rosa, Carlo Alberto Schena, Vito Laterza, Giuseppe Quero, Claudio Fiorillo, Antonia Strippoli, Carmelo Pozzo, Valerio Papa and Sergio Alfieri
Cancers 2022, 14(22), 5542; https://doi.org/10.3390/cancers14225542 - 11 Nov 2022
Cited by 5 | Viewed by 1866
Abstract
Surgery still represents the mainstay of treatment of all stages of gastric cancer (GC). Surgical resections represent potentially curative options in the case of early GC with a low risk of node metastasis. Sentinel lymph node biopsy and indocyanine green fluorescence are novel [...] Read more.
Surgery still represents the mainstay of treatment of all stages of gastric cancer (GC). Surgical resections represent potentially curative options in the case of early GC with a low risk of node metastasis. Sentinel lymph node biopsy and indocyanine green fluorescence are novel techniques which may improve the employment of stomach-sparing procedures, ameliorating quality of life without compromising oncological radicality. Nonetheless, the diffusion of these techniques is limited in Western countries. Conversely, radical gastrectomy with extensive lymphadenectomy and multimodal treatment represents a valid option in the case of advanced GC. Differences between Eastern and Western recommendations still exist, and the optimal multimodal strategy is still a matter of investigation. Recent chemotherapy protocols have made surgery available for patients with oligometastatic disease. In this context, intraperitoneal administration of chemotherapy via HIPEC or PIPAC has emerged as an alternative weapon for patients with peritoneal carcinomatosis. In conclusion, the surgical management of GC is still evolving together with the multimodal strategy. It is mandatory for surgeons to be conscious of the current evolution of the surgical management of GC in the era of multidisciplinary and tailored medicine. Full article
(This article belongs to the Special Issue Management of Gastric Cancer)
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-5
Back to TopTop